One study indicated that melanoma tumors treated with anti-CTLA-4 therapy exhibit significant changes, including an elevated tumor mutation burden, increased inflammatory characteristics, and alterations in cell cycle processes, compared to untreated tumors (31) (Figure 2). The gene discussed is CTLA4; the disease is melanoma.